Tranexamic acid for post-partum haemorrhage: What, who and when
Autor: | Katharine Ker, Ian Roberts, Amy Brenner, Haleema Shakur-Still |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
Tranexamic acid
Article Postpartum haemorrhage 03 medical and health sciences 0302 clinical medicine Pregnancy Medicine Childbirth Humans 030212 general & internal medicine Post partum 030219 obstetrics & reproductive medicine business.industry Fibrinolysis Anti-Fibrinolytic agents Postpartum Hemorrhage Postpartum Period Parturition Obstetrics and Gynecology General Medicine Bleed Antifibrinolytic Agents 3. Good health Anesthesia Female Maternal health business medicine.drug Haemostasis |
Zdroj: | Best Practice & Research. Clinical Obstetrics & Gynaecology |
ISSN: | 1521-6934 |
Popis: | Tranexamic acid reduces bleeding by inhibiting the breakdown of blood clots. It is cost-effective and heat-stable with a long shelf life. In the WOMAN trial, tranexamic acid reduced deaths due to bleeding with no increase in thromboembolic events. The effect was greatest when women received tranexamic acid within 3 h of childbirth (RR = 0.69, 95% CI 0.52–0.91). The WHO recommends that women with post-partum haemorrhage receive 1 g tranexamic acid intravenously as soon as possible after giving birth, followed by a second dose if bleeding continues after 30 min or restarts within 24 h since the first dose. Urgent treatment is critical because women with post-partum haemorrhage bleed to death quickly, and tranexamic acid is most effective when given early. Evidence suggests there is no benefit when the drug is given more than 3 h after bleeding onset. Alternative routes of administration and use of tranexamic acid in the prevention of post-partum haemorrhage are research priorities. Highlights • Tranexamic acid reduces bleeding by inhibiting the enzymatic breakdown of fibrin. • It is the only treatment proven to reduce deaths due to haemorrhage in a randomised trial. • It is a safe, effective and affordable treatment for post-partum haemorrhage. • Early administration reduces the risk of exsanguination by one-third. • Urgent treatment is critical: treat as soon as possible and not >3 h after birth. |
Databáze: | OpenAIRE |
Externí odkaz: |